Jeffrey Schneider, M.D.


Digestive CARE is committed to offering our patients the highest quality and most comprehensive CARE you would expect from our experts in Gastroenterological care. We believe our clinical research is a critical extension to our practice, allowing our physicians to continue to evaluate and offer cutting edge therapies to our patients and the community.

For over two (2) decades, the physicians of Digestive CARE have been influential leaders in clinical research, including performing hundreds of studies on the advancement of treatments for Hepatitis,  Inflammatory Bowel Disease and Irritable Bowel Syndrome, to name only a few. The safety of our patients is always our priority and as such, we participate only in research studies overseen by the FDA or National regulatory boards.


For more information, contact Digestive CARE Research at




Now enrolling for the following studies:

C Difficile

Clostridium difficile colitis or pseudomembranous colitis is colitis (inflammation of the large intestine) resulting from infection with Clostridium difficile, a spore-forming bacterium. It causes an infectious diarrhea called C. difficile associated diarrhea (CDAD). The colitis is thought to occur when this bacterium replaces normal gut flora that has been compromised, usually following antibiotic treatment for an unrelated infection. The disturbance of normal healthy bacteria may provide C. difficile an opportunity to overrun the intestinal microbiome.

In order to participate in this study, you must meet all of the following criteria:

  • Male or Female between the ages of 18-80
  • Diagnosed with Clostridium difficile infection by a qualified physician
  • Symptoms alleviated with antibiotic treatment
  • Infection returning or persisting after 3 rounds of antibiotic treatment during which symptoms were controlled

If you think you may be a candidate for enrollment , contact Digestive CARE Research at

Contact Information

General Information:
Office hours: 9 am to 5 pm
Monday through Friday